Literature DB >> 33807769

Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.

Ashley N Brown1, Gary Strobel2, Kaley C Hanrahan1, Joe Sears3.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remdesivir is only approved for severe COVID-19 cases. Here, we evaluated the antiviral potential of a Propylamylatin formula, which is a mixture of propionic acid and isoamyl hexanoates. The Propylamylatin formula was investigated in gaseous and liquid phases against 1 mL viral suspensions containing 105 PFU of SARS-CoV-2. Viral suspensions were sampled at various times post-exposure and infectious virus was quantified by plaque assay on Vero E6 cells. Propylamylatin formula vapors were effective at inactivating infectious SARS-CoV-2 to undetectable levels at room temperature and body temperature, but the decline in virus was substantially faster at the higher temperature (15 min versus 24 h). The direct injection of liquid Propylamylatin formula into viral suspensions also completely inactivated SARS-CoV-2 and the rapidity of inactivation occurred in an exposure dependent manner. The overall volume that resulted in 90% viral inactivation over the course of the direct injection experiment (EC90) was 4.28 µls. Further investigation revealed that the majority of the antiviral effect was attributed to the propionic acid which yielded an overall EC90 value of 11.50 µls whereas the isoamyl hexanoates provided at most a 10-fold reduction in infectious virus. The combination of propionic acid and isoamyl hexanoates was much more potent than the individual components alone, suggesting synergy between these components. These findings illustrate the therapeutic promise of the Propylamylatin formula as a potential treatment strategy for COVID-19 and future studies are warranted.

Entities:  

Keywords:  COVID-19; Muscodor albus; SARS-CoV-2; antiviral agent; volatile organic compounds

Mesh:

Substances:

Year:  2021        PMID: 33807769      PMCID: PMC7999574          DOI: 10.3390/v13030415

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  20 in total

Review 1.  Natural Products as Sources of New Drugs from 1981 to 2014.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2016-02-07       Impact factor: 4.050

2.  Volatile antimicrobials from Muscodor albus, a novel endophytic fungus.

Authors:  G A Strobel; E Dirkse; J Sears; C Markworth
Journal:  Microbiology       Date:  2001-11       Impact factor: 2.777

3.  Nasal mucociliary clearance in health and disease.

Authors:  V K Pandya; R S Tiwari
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2006-10

Review 4.  Covid-19 and the digestive system.

Authors:  Sunny H Wong; Rashid Ns Lui; Joseph Jy Sung
Journal:  J Gastroenterol Hepatol       Date:  2020-04-19       Impact factor: 4.029

5.  SARS-CoV-2 productively infects human gut enterocytes.

Authors:  Mart M Lamers; Joep Beumer; Jelte van der Vaart; Bart L Haagmans; Hans Clevers; Kèvin Knoops; Jens Puschhof; Tim I Breugem; Raimond B G Ravelli; J Paul van Schayck; Anna Z Mykytyn; Hans Q Duimel; Elly van Donselaar; Samra Riesebosch; Helma J H Kuijpers; Debby Schipper; Willine J van de Wetering; Miranda de Graaf; Marion Koopmans; Edwin Cuppen; Peter J Peters
Journal:  Science       Date:  2020-05-01       Impact factor: 47.728

6.  Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV.

Authors:  Miriam E R Darnell; Kanta Subbarao; Stephen M Feinstone; Deborah R Taylor
Journal:  J Virol Methods       Date:  2004-10       Impact factor: 2.014

7.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Authors:  Neeltje van Doremalen; Trenton Bushmaker; Dylan H Morris; Myndi G Holbrook; Amandine Gamble; Brandi N Williamson; Azaibi Tamin; Jennifer L Harcourt; Natalie J Thornburg; Susan I Gerber; James O Lloyd-Smith; Emmie de Wit; Vincent J Munster
Journal:  N Engl J Med       Date:  2020-03-17       Impact factor: 91.245

8.  Effect of Environmental Conditions on SARS-CoV-2 Stability in Human Nasal Mucus and Sputum.

Authors:  M Jeremiah Matson; Claude Kwe Yinda; Stephanie N Seifert; Trenton Bushmaker; Robert J Fischer; Neeltje van Doremalen; James O Lloyd-Smith; Vincent J Munster
Journal:  Emerg Infect Dis       Date:  2020-06-08       Impact factor: 6.883

9.  Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.

Authors:  Baofu Qiao; Monica Olvera de la Cruz
Journal:  ACS Nano       Date:  2020-08-04       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.